研發產品概況
研發中新藥 Pipeline (SIF緩釋藥物輸送平臺)
| Product / Indication | Research | Pre-clinical | Phase I | Phase II | Phase III | NDA/MAA | Market |
|---|---|---|---|---|---|---|---|
| CAMCEVI (Leuprolide, FP-001) | |||||||
| Prostate Cancer, CAMCEVI 42 mg  | | ||||||
| Prostate Cancer, CAMCEVI 21 mg  | | ||||||
| Central Precocious Puberty  | | ||||||
| Premenopausal Breast Cancer | | ||||||
| FP-014 (Triptorelin) | |||||||
| Prostate Cancer | | ||||||
| FP-016 (Undisclosed) | |||||||
| Neurology/Psychiatry | | ||||||
研發中新藥 Pipeline (NCE 合理性藥物設計)
| Product / Indication | Research | Pre-clinical | Phase I | Phase II | Phase III | NDA/MAA | Market |
|---|---|---|---|---|---|---|---|
| FP-025 (aderamastat, MMP-12 Inhibitor) | |||||||
| POC Phase 2 study in allergic asthma patients | | ||||||
| Cardiac Sarcoidosis  | | ||||||
| FP-020 (linvemastat, MMP-12 Inhibitor) | |||||||
| Asthma or COPD  | | ||||||
| Inflammatory bowel disease (IBD) | | ||||||
| FP-MMP-12 inhibitor 1 | |||||||
| ILD, including Idiopathic pulmonary fibrosis (IPF) | | ||||||
| FP-MMP-12 inhibitor 2 | |||||||
| Neurology | | ||||||
| FP-045 (mirivadelgat, ALDH2 Activator) | |||||||
| POC Phase 1b/2 study in Fanconi Anemia (Pediatric formulation)  | | ||||||
| Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (solid formulation)  | | ||||||
| FP-ALDH2 Activator 1 | |||||||
| Cardiovascular, Renal and Metabolic Diseases (CVRM) | | ||||||
| FP-ALDH2 Activator 2 | |||||||
| Neurology | | ||||||